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John A. Hanover3, Dan Doherty4, Miao He5, May Christine V. Malicdan1*, William A. Gahl1  
and Cornelius F. Boerkoel1,10
Abstract 
Background: The discovery of disease pathogenesis requires systematic agnostic screening of multiple homeostatic 
processes that may become deregulated. We illustrate this principle in the evaluation and diagnosis of a 5‑year‑
old boy with Joubert syndrome type 10 (JBTS10). He carried the OFD1 mutation p.Gln886Lysfs*2 (NM_003611.2: 
c.2656del) and manifested features of Joubert syndrome.
Methods: We integrated exome sequencing, MALDI‑TOF mass spectrometry analyses of plasma and cultured dermal 
fibroblasts glycomes, and full clinical evaluation of the proband. Analyses of cilia formation and lectin staining were 
performed by immunofluorescence. Measurement of cellular nucleotide sugar levels was performed with high‑
performance anion‑exchange chromatography with pulsed amperometric detection. Statistical analyses utilized the 
Student’s and Fisher’s exact t tests.
Results: Glycome analyses of plasma and cultured dermal fibroblasts identified abnormal N‑ and O‑linked glycosyla‑
tion profiles. These findings replicated in two unrelated males with OFD1 mutations. Cultured fibroblasts from affected 
individuals had a defect in ciliogenesis. The proband’s fibroblasts also had an abnormally elevated nuclear sialylation 
signature and increased total cellular levels of CMP‑sialic acid. Ciliogenesis and each glycosylation anomaly were 
rescued by expression of wild‑type OFD1.
Conclusions: The rescue of ciliogenesis and glycosylation upon reintroduction of WT OFD1 suggests that both con‑
tribute to the pathogenesis of JBTS10.
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Background
Joubert syndrome (JBTS) is a rare genetic condition char-
acterized by hypotonia, developmental delay, cerebellar 
dysfunction, a neuroradiologic “molar tooth sign” (MTS), 
and variable involvement of other systems [1, 2]. JBTS is 
a ciliopathy, and mutations in more than 30 genes encod-
ing products localizing primarily to and around the cilia 
are implicated in its pathogenesis [3, 4]. The genetic 
locus associated with JBTS type 10 (OMIM 300804) is 
OFD1; mutations in this gene also cause the X-linked 
dominant disorder orofaciodigital syndrome I (OFDI, 
OMIM 311200), the X-linked recessive disorder Simp-
son–Golabi–Behmel syndrome, type 2 (SGBS2, OMIM 
300209), and an X-linked form of retinitis pigmentosa 
(RP23, OMIM 300424) [5].
The ciliary function of the OFD1 protein has not been 
fully elucidated, although it does play a role in primary 
ciliogenesis and regulation of ciliary length [6, 7]. Loss of 
OFD1 in animals causes defects in left/right axis devel-
opment, ciliogenesis, and neurological development 
[8–10]. These phenotypes are consistent with features 
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observed in other ciliopathy disorders and reflect the role 
of primary cilia in the Shh, Wnt, and planar cell polarity 
(PCP) signaling pathways [4]. In the centrosome, OFD1 
interacts with lebercilin, a key protein in the pathogen-
esis of Leber congenital amaurosis [11, 12]. Based upon 
its nuclear localization, there is a hypothesis that OFD1 
plays a role in chromatin remodeling [13].
The National Institutes of Health Undiagnosed Dis-
ease Program (NIH UDP) evaluates individuals with rare 
and undiagnosed diseases and an indication of a genetic 
etiology. Physicians across multiple specialties consult 
on each patient to obtain a full phenotypic description. 
In addition to targeted diagnostic tests, the NIH UDP 
implements broader, agnostic screens of exome, glycome, 
and metabolome.
Herein we report the evaluation of a 5-year-old boy 
with Joubert syndrome secondary to mutation in OFD1. 
His cultured dermal fibroblasts had impaired ciliogen-
esis, and his plasma and cultured dermal fibroblasts 
had abnormal N- and O-linked glycosylation profiles. 
Glycomic evaluation of two unrelated individuals with 
JBTS10 detected similar plasma and fibroblast N- and 
O-linked glycosylation profiles. Cultured fibroblasts from 
the proband also had increased CMP-sialic acid. Over-
expression of wild-type OFD1 cDNA rescued both the 
glycosylation and ciliary phenotypes. We posit, therefore, 
that glycosylation anomalies are a previously undocu-
mented contributor to the pathogenesis of JBTS10.
Methods
Patient enrollment and consent
The proband, UDP-3331, was evaluated in the National 
Institutes of Health Undiagnosed Diseases Program (NIH 
UDP) and was enrolled in clinical protocol 76-HG-0238, 
approved by the NHGRI Institutional Review Board. His 
mother, UDP-4786, provided informed consent. NIH-452 
was enrolled in protocol “Clinical and Molecular Inves-
tigations into Ciliopathies” (Trial NCT00068224); his 
legal guardian provided informed consent. Both proto-
cols conform to the 1964 Helsinki Declaration and subse-
quent amendments standard for patient protection.
Variant identification and Sanger sequencing
Genomic DNA was extracted from peripheral whole 
blood of UDP-3331 and UDP-4786 using the Gen-
tra Puregene Blood Kit (Qiagen, Valencia, CA) and 
an AutoGen FlexStar with standard procedures. The 
DNA of all family members was subjected to an inte-
grated set of genomic analyses including high-density 
single-nucleotide polymorphism (SNP) arrays and 
whole exome sequencing (WES) as described previ-
ously [14–17]. WES was performed on these indi-
viduals using the Illumina HiSeq2000 platform and 
the TrueSeqV2 capture kit (Illumina, San Diego, CA). 
Sample library preparation, sequencing, and analysis 
were performed using the standard NIH Intramural 
Sequencing Center (NISC) pipeline [18]. Sequence data 
were aligned to human reference genome (hg19) using 
Novoalign (Novocraft Technologies, Selangor, Malay-
sia). To test for copy number variants and to form seg-
regation BED files for exome analysis, Omni Express 12 
(hg19) SNP arrays were run on genomic DNA from all 
family members as described [14]. Variants listed in the 
Variant Call Files (VCFs) were filtered based on rarity, 
Mendelian segregation, and predicted deleteriousness 
on the Cartagenia platform (Cartagenia N.V., Leuven, 
Belgium).
Exome variants were filtered using ExAC release 0.3 
population frequency data (MAF  <  0.02, 95% confi-
dence interval; homozygote count ≤25) and UDP found-
ers cohort population frequency data (variant allele 
count  <8). Variants were prioritized based on coding 
effect (nonsynonymous, frameshift, stopgain, stoploss, 
startloss, inframe), proximity to splice sites (within 20 
base pairs of a canonical splice site into the intron, or 5 
base pairs into the exon), and CADD v1.3 Phred scores. 
Using the Integrative Genome Viewer (https://www.
broadinstitute.org/igv/home), we assessed the quality 
of alignment and genotype call of variants. The single-
nucleotide deletion identified by exome sequencing was 
confirmed using Sanger sequencing of the genomic DNA 
from both UDP-3331 and UDP-4786; the forward primer 
used was 5′-AGTAGGGTACAGTTCAAGGAGTGG-3′ 
and the reverse primer was 5′-ATTCTGTGCAGC-
CTTTCCCAC-3′. DNA amplification was performed 
with Platinum Pfx DNA polymerase (ThermoFisher Sci-
entific, Waltham, Massachussets) and standard thermal 
cycling protocol with an annealing temperature of 55 °C 
for a total of 30 cycles.
OFD1 cloning
Wild-type (WT) cDNA expression constructs were made 
by PCR amplification of the OFD1 cDNA sequence from 
a sequence-verified TrueORF Gold clone (RC220154, 
Origene, Rockville, Maryland). The PCR product was 
cloned into pENTR/D-TOPO vector (ThermoFisher Sci-
entific) and subcloned into pLENTI6.3/V5-DEST (Ther-
moFisher Scientific) using the Gateway LR Clonase II 
enzyme (ThermoFisher Scientific). Clones were verified 
by Sanger sequencing.
Lentiviral infection and rescue
Lentivirus was generated by transfecting 293FT cells 
with the pLENTI6.3-OFD1 construct and the ViraPower 
HiPerform Lentiviral Gateway expression kit (Ther-
moFisher Scientific) as per the manufacturer’s protocol. 
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Lentiviral culture supernatant was applied to patient 
and adult WT control cells in the presence of polybrene 
(10  µg/mL, EMD Millipore, Billerica, Massachusetts). 
Stable integration of the OFD1 construct was selected by 
addition of 5 µg/mL blasticidin (ThermoFisher Scientific) 
to the medium and confirmed by qPCR and immunob-
lotting. Subsequently, retention of the integrated active 
OFD1 construct was selected by growth in medium sup-
plemented with 2.5 µg/mL blasticidin.
Primary fibroblast isolation and culture
Primary dermal fibroblasts from UDP-3331 were derived 
from a forearm skin punch biopsy. Additional fibroblast 
lines were obtained from ATCC (ATCC-PCS-201-012, 
Manassas, Virginia) and Coriell Repository [GM00409 
(7 y.o. male) and GM08398 (8 y.o. male), Camden, New 
Jersey]. The established fibroblast lines were cultured 
in growth medium, consisting of Dulbecco’s Modified 
Eagle Medium (DMEM) with 1 g/L glucose (low glucose 
DMEM), 10% heat inactivated fetal bovine serum (HI 
FBS, ThermoFisher Scientific), and 1% antibiotic/anti-
mycotic (ThermoFisher Scientific). Culture of primary 
fibroblasts for glycome analysis utilized α-MEM (Cellgro, 
Mediatech, Manassas, Virginia) supplemented with 15% 
HI FBS and 1% antibiotic/antimycotic for 24–48 h prior 
to cell harvest.
RNA isolation and qRT‑PCR analysis
RNA extraction from cultured dermal fibroblasts was 
performed as per the manufacturer’s protocol using the 
Qiagen RNeasy Mini kit (Qiagen, Hilden, Germany) 
with on-column DNA digestion. Equal amounts of 
RNA were reverse-transcribed from each cell line using 
the OmniScript cDNA first-strand synthesis kit (Qia-
gen). SYBR Green reagent (Qiagen) was used to amplify 
OFD1 and GAPDH for a ∆∆Ct relative quantifica-
tion of OFD1 expression on an ABI7500 Fast RealTime 
PCR machine with the Melt Curve option. Quantifica-
tion and quality control parameters were according to 
the standard manufacturer’s settings. Primers used for 
OFD1 were 5′-CGGAGCAGAAAGTGGGTCTTT-3′ 
and 5′-TGGCATGTTCCCTGCAGATT-3′; primers for 
GAPDH were 5′-TGCACCACCAACTGCTTAGC-3′ and 
5′-GGCATGGACTGTGGTCATGAG-3′.
Immunoblotting
Fibroblasts were cultured to near 100% confluence, 
rinsed twice with PBS, and harvested by in-dish lysis with 
RIPA buffer (Sigma-Aldrich, St. Louis, Missouri) supple-
mented with 1× complete Ultra Protease Inhibitor Cock-
tail (Sigma-Aldrich). Total protein concentration of the 
lysates was determined using the DC Protein Assay (Bio-
Rad, Hercules, California) and equal amounts of protein 
were run for each sample on SDS-PAGE gels (4–12% 
gradient, BioRad) in SDS–Tris–glycine buffer. Proteins 
were transferred using a standard wet-transfer method to 
Immobilon-FL PVDF membranes in Tris–glycine buffer 
with 20% methanol. Blocking was performed with Odys-
sey blocking buffer in PBS (LiCor, Lincoln, Nebraska); 
primary antibodies were incubated overnight at 4  °C in 
fresh blocking solution. Membranes were washed three 
times with PBS-Tween 20 (0.1%) and incubated with 
Odyssey near-IR conjugated secondary antibodies for 
1 h in Odyssey blocking buffer with Tween-20 (0.1%) and 
SDS (0.2%). Prior to imaging on a LiCor Odyssey CLx, 
membranes were washed three times with PBS-Tween 
20 and rinsed once with diH2O. Band quantification and 
analysis were performed using the CLx imaging soft-
ware (LiCor). Antibodies used were anti-OFD1 (1:1000, 
TA308968, Origene), anti-α-tubulin (1:5000, ab7291, 
Abcam; Cambridge, Massachusetts), anti-rabbit IR800 
(1:10,000, 925–32,211, LiCor), and anti-mouse IR680 
(1:10,000, 925–68,020, LiCor).
Immunofluorescence of cultured fibroblasts
Staining of cultured fibroblasts, either with antibodies 
or lectins, utilized a similar protocol with minor varia-
tions detailed  below. Cultured cells were fixed with 4% 
paraformaldehyde in phosphate-buffered saline (PBS) 
at room temperature for 10  min, or in ice-cold 100% 
methanol at −20 °C for 15 min, or a combination of both. 
The fixed cells were washed three times with PBS. Par-
aformaldehyde-fixed cells were permeabilized with 0.5% 
NP-40 detergent in PBS at room temperature for 10 min 
then washed three times in PBS. The fixed and permea-
bilized cells were then incubated with a blocking buffer 
for 1 h. Primary staining reagent(s) were diluted in block-
ing buffer and applied for 1–2 h at room temperature or 
overnight at 4  °C. The cells were then washed with PBS 
three times. The cells were then incubated with sec-
ondary detection reagents with fluorophore conjugates 
diluted in blocking buffer for 1  h at room temperature. 
After washing the cells three times with PBS, the cover-
slips were mounted onto slides with the indicated mount-
ing media prior to imaging.
OFD1 localization and cell morphology analysis
Cells were grown on 12-mm round coverslips to 50–70% 
confluence at the time of fixation. Cells were fixed either 
in paraformaldehyde or methanol, depending upon man-
ufacturers’ recommendations for the primary antibodies. 
The blocking reagent used was 4% BSA (bovine serum 
albumin) in PBS, and the primary antibodies used were 
OFD1 (1:100, Origene), ɣ-Tubulin (1:1000; T5326, Sigma-
Aldrich), α-tubulin (1:2000, ab7291, Abcam), PCM1 
(1:100, sc-50164, SantaCruz Biotechnology, Dallas, 
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Texas), GM-130 (1:250, 610822, BD Biosciences, San 
Jose, California), TGN-46 (1:200, GTX74290, Genetex, 
Irvine, California), or KDEL (1:100, ab12223, Abcam). 
Alexa Fluor conjugated secondary antibodies used were 
Alexa488 Donkey anti-Rabbit, Alexa555 Donkey anti-
Mouse, and Alexa647 Donkey anti-Rabbit (ThermoFisher 
Scientific). Where indicated, DNA was counterstained 
with Hoechst 33342 (ThermoFisher Scientific) and cov-
erslips were rinsed with PBS. The mounting medium 
was ProLong Gold antifade mounting medium (Ther-
moFisher Scientific) and the slides were imaged using a 
20× or 40× objective on a Zeiss LSM 700 confocal laser-
scanning microscope (Carl Zeiss Microscopy, GmbH, 
Jena, Germany).
Cilia measurements
Fibroblasts were grown to 80% confluence and then 
serum starved for 48  h. Cells were fixed with 4% para-
formaldehyde for 5  min at room temperature followed 
by ice-cold methanol for 4  min at −20  °C. The block-
ing buffer used was PBS containing 10% normal donkey 
serum, 1% BSA, and 0.1% triton X-100 for 1  h. Fixed 
cells were incubated overnight with primary antibodies 
(1:1000–1:2000, mouse anti-acetylated Tubulin, T6793, 
SigmaAldrich; 1:200, goat anti-γ tubulin, sc-7396, Santa 
Cruz). Secondary antibodies used were AlexaFluor 
conjugated secondary antibodies (Life Technologies). 
Coverslips were mounted using Fluoromount G with 
4′,6-diamidino-2-phenylindole (DAPI) (Southern Bio-
tech, 0100-20, Birmingham, Alabama).
Fourteen image z-stacks with 0.3  mm spacing were 
taken with a CoolSNAP HQ2 digital monochrome cam-
era (Photometrics, Tucson, Arizona, USA) through a 
Marianas live cell imaging system (Intelligent Imag-
ing Innovations, Denver, Colorado, USA) using a Plan 
Apochromat 63X, 1.4 NA oil objective.
Percentage of ciliated cells and length measurements 
were made in FIJI on 16-bit sum projection images of 
z-stacks. Cilia were defined as linear acetylated tubulin-
positive structures >1-μm long with a punctate gamma-
tubulin signal at one end. The percentage of ciliated 
cells was determined by dividing the number of ciliated 
cells by the number of DAPI-positive nuclei in the same 
images. To measure cilium length, we manually painted 
a mask over each cilium (defined by acetylated tubulin) 
with a 3 pixel-wide brush, skeletonized the cilium mask, 
and applied the maximum branch length function.
Lectin staining of cultured fibroblasts
Biotinylated Maackia amurensis lectin II (MAL II), fluo-
rescein Sambucus nigra (elderberry) bark lectin (SNA), 
and rhodamine Peanut Agglutinin (PNA) were obtained 
from Vector Laboratories (Burlingame, California). Cells 
were seeded at 0.5 × 105 per 12-mm round coverslip and 
cultured overnight. The cells were fixed with paraform-
aldehyde or methanol as indicated in the text. Blocking 
was performed with 4% BSA in PBS, followed by pri-
mary incubation with MAL II, SNA, and/or PNA lectins 
(20  µg/mL). Detection of biotinylated MAL II required 
secondary incubation with Streptavidin AlexaFluor 350 
(S-11,249, ThermoFisher Scientific). In cells without 
MAL II staining, DNA was stained with Hoechst 33342 
(ThermoFisher Scientific). Coverslips were mounted on 
slides using ProLong Gold anti-fade reagent then imaged 
using a 20× objective on a Zeiss LSM 700 confocal laser-
scanning microscope. Image analysis was performed 
using ImageJ software [19].
Neuraminidase treatment and cilia measurement
Adult WT fibroblasts were plated directly on coverslips 
at 0.5 ×  105 cells per 12-mm coverslip density, allowed 
to adhere overnight, and then grown for additional 48 h 
in the absence of serum. Half of the coverslips were 
washed with Hank’s Balanced Salt Solution (HBSS) and 
then incubated for 1 h at 37 °C in 1 mU/mL neuramini-
dase (Sigma, N2133) dissolved in HBSS. Untreated cells 
were left in serum-free media. Cells were subsequently 
washed three times in PBS and then fixed using ice-cold 
methanol. Staining for cilia utilized anti-ARL13B (1:250, 
ProteinTech, Rosemont, Illinois) and anti-gamma tubulin 
(1:250, Sigma-Alridch) with Hoechst 33342 DNA coun-
terstaining. DNA counterstaining in conjunction with 
lectin staining, which was performed as stated above, uti-
lized the far-red dye DRAQ5 (Abcam). Cilia were defined 
as above and measured with FIJI software; the percentage 
of ciliated cells was defined as above.
Glycome analysis
Primary dermal fibroblasts were cultured and processed 
to release N- and O-linked glycans as previously reported 
[20]. Fibroblasts were cultured in DMEM with 10% HI 
FBS and 1% antibiotic/antimycotic to 80% confluence 
in a 15-cm culture disk. After one rinse with PBS, the 
medium was changed to α-MEM containing 1000 mg/L 
d-glucose, 15% HI FBS, and 1% antibiotic–antimycotic. 
Upon reaching 100% confluence, the cells were washed 
twice with PBS then harvested using a cell scraper. The 
cells were then pelleted in PBS by centrifugation. Fibro-
blast pellets were lysed in 300 µL PBS with sonication and 
400  µg of total glycoprotein was collected from the cell 
lysate. Free glycans were removed by Ultracel-10k Cen-
trifugal filter (EMD Millipore, Billerica, Massachusetts) 
and the enriched glycoproteins were divided into 200-µg 
aliquots for N-glycan and O-glycan preparation. N-linked 
glycans were released from 200 µg of total glycoproteins 
or 10-µL plasma samples using PNGase F digestion (New 
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England Biolabs, Ipswich, Massachusetts, USA). The 
released N-linked glycans from plasma or cells were puri-
fied and desalted by solid-phase extraction using a Sep-
Pak C18 and carbograph column. O-linked glycans were 
released using β-elimination with sodium borohydride. 
O-linked glycans from plasma or cells were purified and 
desalted using an AG 50  W-X8 resin cation exchange 
column. N-linked glycans or O-linked glycans were per-
methylated with sodium hydroxide and iodomethane 
in dimethyl sulfoxide (DMSO) as described before [21]. 
Following permethylation, glycans were extracted with 
water/chloroform (2:1, vol/vol) for four times and dried. 
Samples were then dissolved in 50% methanol, spotted 
with 11% 2,5-dihydroxylbenzoic acid matrix (1:1 vol/vol), 
and measured by MALDI-TOF using the positive mode 
on Ultraflex MALDI-TOF/TOF system (BrunkerDalton-
ics, Billerica, Massachusetts).
Nucleotide sugar analysis
Fibroblasts were cultured in growth medium in 15-cm 
culture disks until 90–100% confluent, rinsed with PBS 
and harvested by scraping into PBS. Cells were counted 
using an automated cell counter (BioRad TC20) and 
pelleted at 500 RCF for 5  min. Nucleotide sugars were 
extracted based on previously published methods [22, 
23]. Briefly, cell pellets were lysed in 70% ethanol, 300 µL 
of ethanol per million cells, and subjected to three 
rounds of sonication for 5  s at 15% amplitude. An ali-
quot of lysate was taken for total protein quantification. 
Lysates were pelleted at 16,000×g for 10 min at 4 °C and 
the supernatant was collected and lyophilized. The lyo-
philized supernatant was resuspended in 40 mM sodium 
phosphate buffer (pH 9.2) at 60 µL per million cells and 
further diluted based on total protein from the initial 
lysate relative to adult WT. The supernatant was applied 
to a Millipore spin column (10kD MW cut off) and spun 
for 30  min at 16,000×g. The extracted nucleotide sug-
ars were analyzed by high-performance anion-exchange 
chromatography with pulsed amperometric detection 
(HPAEC-PAD) on a Dionex instrument as previously 
reported [22] and were quantified by comparison to a 
standard curve of dilutions of CMP-sialic acid (C8271, 
Sigma-Aldrich) in 40 mM sodium phosphate.
Results
Clinical report
The proband, UDP-3331, is a 5-year-old male, born 
to unaffected parents; he had an unaffected sister. At 
14  months, he presented with severe feeding problems 
requiring placement of a G-tube. At 18 months, he was 
evaluated for hypotonia and dysmorphia. Over the next 
4  years, his documented features included oral motor 
dysfunction, sleep apnea, myopathy, developmental 
delay, easy bruising, hypertrichosis, rocker bottom feet, 
and dysmorphic facial features, including a notched 
upper lip and submucous cleft palate. Following 5 years 
of non-diagnostic evaluations, the proband was evaluated 
at the NIH UDP. His brain MRI revealed a molar tooth 
sign (Fig.  1a) that, combined with his clinical features 
(Table 1), suggested a diagnosis of Joubert syndrome.
Exome sequencing identifies an OFD1 mutation
Analysis of exome sequence data for variants in 
genes associated with Joubert syndrome revealed 
NM_003611.2: c.2656del, a maternally inherited hemizy-
gous mutation in OFD1. Sanger sequencing confirmed 
the variant in the proband and mother (UDP-3331 and 
UDP-4786, respectively; Fig. 1b) and refined the diagno-
sis to JBTS10. Considering the apparently normal phe-
notype of the mother, no further testing or analysis of 
samples from individual UDP-4786 was performed.
The OFD1 mutant protein is stable and appropriately 
localized
NM_003611.2: c.2656del, which occurred in the 20th 
exon, is predicted to encode a frameshift leading to a 
premature stop codon, p.Gln886Lysfs*2. To test if this 
mutation caused nonsense-mediated mRNA decay and 
thereby loss of OFD1 function, we measured OFD1 
mRNA levels in cultured dermal fibroblasts by qRT-PCR. 
Following normalization to GAPDH mRNA abundance, 
the UDP-3331 OFD1 mRNA levels were approximately 
30% of those in control dermal fibroblasts (Fig.  1c), a 
finding consistent with loss of function and previous 
reports [11]. OFD1 protein levels, as measured by immu-
noblotting, were approximately 50% of those in control 
dermal fibroblasts following normalization to α-tubulin 
(Fig. 1d). Lentiviral transduction of a WT copy of OFD1 
cDNA into the dermal fibroblasts of UDP-3331 partially 
rescued OFD1 mRNA and protein expression (Fig. 1c, d).
We next determined the intracellular localization of 
the residual OFD1 protein by immunofluorescent stud-
ies of dermal fibroblasts. In both UDP-3331 and control, 
residual OFD1 localized with the centrosome as judged 
by co-localization with centrosome markers ɣ-tubulin 
and PCM1 (Fig.  2a). Notably, in both affected and con-
trol fibroblasts, we observed variable co-localization of 
all three centrosomal proteins; the variability is likely 
due to the presence of non-centrosomal aggregates of 
PCM1 [24] and cell-cycle differences among the popu-
lation of cells resulting in variable ɣ-tubulin localization 
to the centrosome [25, 26]. Microtubule morphology 
(α-tubulin) appeared to be unaffected in the JBTS10 cell 
line as compared to control (Fig. 2b).
Given the role of the basal body and microtubules in 
regulating trafficking through the secretory pathway, we 
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also examined the structure of these compartments in 
the affected cells [27]. As judged by immunofluorescence, 
there was no change in the morphology of the endoplas-
mic reticulum and the cis- and trans-Golgi of UDP-3331 
compared to control adult dermal fibroblasts (Fig. 2c, d).
Decreased cilium number in OFD1 p.Gln886Lysfs*2 mutant 
cells
The above observations raised the question as to whether 
the remaining OFD1 protein that localized to the cen-
trosome in UDP-3331 dermal fibroblasts was sufficient 
to support ciliogenesis. Comparable to a fetal-affected 
JBTS10 cell line (UW172-4, NM_003611.2: c.277G  >  T, 
p.Val93Phe [28]), UDP-3331 dermal fibroblasts showed a 
decreased ability to form cilia that was rescued to near 
WT levels by expression of WT OFD1 (Fig. 3a, b). Thus, 
consistent with previous studies [8], the reduction in 
OFD1 mRNA and protein levels in UDP-3331 dermal 
fibroblasts is sufficient to impede cilia formation.
JBTS10 tissues have OFD1‑dependent anomalies of protein 
glycosylation
Evaluation of UDP-3331 included a screen for anomalies 
of N- and O-linked glycans in plasma and of free oligo-
saccharides in urine. This detected a decrease in mature, 
fully sialylated and galactosylated N-linked glycans at m/z 
2973 (Table  2), whereas monosialo glycan at m/z 2431 
and monosialo, monogalacto glycan at m/z 2227 were 
increased. In plasma O-linked glycans sialylated T anti-
gen (see Additional file 1: Table S1) was decreased, and 
T antigen was at the low end of the normal range. Both 
the plasma N- and O- glycosylation profiles indicated an 
abnormality in sialic acid utilization in the trans-Golgi or 
abnormal metabolism of sialic acids (see Additional file 2: 
Figure S1). Urinary oligosaccharides were within the nor-
mal range. Supporting the association of glycosylation 
anomalies with JBTS10, similar plasma N-linked findings 
were detected in another individual with JBTS10 (NIH-






































































































Fig. 1 Clinical and molecular evidence for Joubert syndrome type 10 diagnosis. a Magnetic resonance imaging of the proband, UDP‑3331, reveals 
the hallmark “molar tooth sign” of the superior cerebellar peduncles (arrow). b Sanger sequencing of both the proband, UDP‑3331, and his mother, 
UDP‑4786, confirms an OFD1 single‑nucleotide deletion (c.2656del) in the proband and maternal inheritance. c Analysis of mRNA transcripts from 
adult control cells (“WT”), UDP‑3331, and UDP‑3331 + OFD1 rescue shows reduced mRNA levels in the proband. Error bars represent standard error 
of four replicates; data are normalized to GAPDH expression and plotted relative to WT OFD1 expression levels. Asterisk indicates p < 0.001 for two‑
tailed, heteroscedastic Student’s t test. d Western blot analysis of OFD1 levels in UDP‑3331, UDP‑3331 + OFD1 and adult WT primary fibroblast lines; 
one representative blot with OFD1 and α‑tubulin is shown in the top panels; average of 3 replicate blots with independent lysates is shown in the 
lower panel. OFD1 levels are normalized to α‑tubulin and plotted relative to WT OFD1 protein levels
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Table 1 Phenotype of JBTS10 patients
Joubert syndrome phenotypes (JBST1; OMIM: 213,300) UDP‑3331 NIH‑452
Head and neck Macrocephaly + +
 Face Prominent forehead − +
High, rounded eyebrows − +
Hemifacial spasms − −
Low‑set ears + +
‘Tilted’ ears − −
 Eyes Abnormal, jerky eye movements − +
Impaired smooth pursuit + +
Impaired saccades + +
Oculomotor apraxia + +
Coloboma of optic nerve − −
Chorioretinal coloboma − −
Epicanthal folds + −
Ptosis − +
 Nose Upturned nose + +
Anteverted nostrils − +
 Mouth Triangular‑shaped open mouth + +
Protruding tongue − +
Rhythmic tongue movements − −
Respiratory Neonatal breathing dysregulation + +
Hyperpnea, episodic − +
Tachypnea, episodic − +
Central apnea + +
Liver Hepatic fibrosis (less common) − +
Central nervous system Delayed psychomotor development + +
Mental retardation/intellectual disability + +
Ataxia − +
Hypotonia + +
Occipital meningocele (less common) + −
Hypoplasia of the brainstem − −
Malformation of brainstem structures + +
‘Molar tooth sign’ on MRI + +
Cerebellar vermis hypoplasia + +
Dysgenesis or agenesis of the cerebellar vermis + +
Deep posterior interpeduncular fossa + +
Thick and elongated superior cerebellar peduncles + +
Behavioral psychiatric manifestations Hyperactivity − −
Aggressiveness − −
Self‑mutilation + +
Additional phenotypes Submucosal cleft palate + −
Notched upper lip or tongue + +
Oral motor dysfunction + +
Recurrent aspiration pneumonia + −
Easy bruising + −
Rockerbottom feet + −
Hypertricosis + −
Moderate hearing loss + −
Double hair whorl + −
GI tube placed in infancy + +
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glycosylation was not tested in this individual due to lim-
ited sample amount.
To exclude the possibility that these findings were non-
specific, we defined the N- and O-linked glycome pro-
file in cultured dermal fibroblasts from JBTS10 patients 
UDP-3331 and UW172-4. Both cell lines had increased 
levels of mono-sialylated N-glycan species compared to 
controls (Table 3). Both cell lines also had abnormal for-
mation of core 2 mature, sialylated O-linked glycans (see 
Additional file 3: Table S2) and thus a relative high abun-
dance of the core 1 species. Core 1 sialylated T antigen 
from cellular protein was not reduced. Each N-glycosyla-
tion abnormality in the cultured JBTS10 dermal fibro-
blasts was partially rescued by expression of WT OFD1 
(Table  3, UDP-3331 +  OFD1). As was observed for the 
plasma results in Table  2, we observed a defect in sia-
lylated glycans in JBTS10 patient fibroblast samples.
Cultured JBTS10 dermal fibroblasts have increased nuclear 
CMP‑sialic acid
To characterize further the glycomic profile abnormali-
ties, we performed lectin immunofluorescence using 
SNA, which preferentially binds to α-2,6-linked sialic 
acids, and MALII, which primarily binds α-2,3-linked 
sialic acids. We observed increased nuclear localization 
of the SNA fluorescently labeled lectin signal in both of 
the JBTS10 dermal fibroblast lines, and this was reduced 
upon rescue with WT OFD1 (Fig. 4a, b, p < 0.05).
Given that the increased nuclear SNA signal was only 
observed in JBTS10 cells fixed with paraformaldehyde 
but not with methanol (Fig.  4c), we hypothesized that 
the SNA-reactive epitope was a small molecule, lipid, 
or protein not preserved by methanol fixation. Unlike 
other nucleotide sugars, which are synthesized in the 
cytosol, CMP-sialic acid (CMP-SA) is synthesized in the 
nucleus and, under aldehyde fixation, could constitute 
a small SNA-reactive epitope [31]. Using HPAEC-PAD, 
comparison of nucleotide sugars levels between UDP-
3331 and adult WT cultured dermal fibroblasts showed 
a 39% increase in CMP-SA in UDP-3331 (Fig.  5a, b); 
introduction of WT OFD1 decreased the CMP-SA levels 
by 50% (p < 0.005, unpaired t test).
Neuraminidase treatment destabilizes cellular primary cilia
Given the association between abnormal sialylation and 
ciliogenesis in the JBTS10 patient lines, we sought to 
examine the effects of disrupting sialylation on cilia sta-
bility in control cells. Following growth in ciliogenic con-
ditions, WT cells were either left untreated or treated 
with neuraminidase to remove sialic acids from the cel-
lular glycoproteome. The neuraminidase used is isolated 
from Clostridium perfringens and can cleave α-2,3-, 
α-2,6-, or α-2,8-linked sialic acids, although it has high-
est affinity for α-2,3-linkages. Cells were then fixed and 
stained for cilia markers and cilia were measured. We 
observed a significant decrease (p < 0.001) in average cilia 
length in WT cells following neuraminidase treatment 
and a modest (p < 0.05) decrease in the number of cili-
ated cells in the population (Fig.  6a–d). Neuraminidase 
treatment successfully disrupted glycoprotein sialylation 
as indicated by increased lectin staining with PNA, which 
strongly binds galactose epitopes normally masked by 
terminal sialic acids (Fig. 6e). Additionally, in the absence 
of neuraminidase treatment, we observed co-localiza-
tion of SNA-reactive epitopes with the cilium marker 
ARL13B, indicating that some proteins localized to the 
primary cilia are sialylated (Fig. 6f ).
Discussion
Herein we have detailed the clinical and molecular phe-
notypes of a boy, UDP-3331, with Joubert syndrome type 
10 (JBTS10). His clinical, molecular, and cellular findings 
are consistent with other reports of JBTS10. Interestingly, 
we observed a global alteration in the N- and O-linked 
glycosylation profiles of three JBTS10 patients. The most 
pronounced and consistent glycosylation change was 
a decrease of mature, fully sialylated N-glycans and an 
increase in total cellular CMP-sialic acid. Within cul-
tured skin fibroblasts, lentiviral rescue with WT OFD1 
cDNA normalized the abnormal glycosylation profiles in 
Table 1 continued
Joubert syndrome phenotypes (JBST1; OMIM: 213,300) UDP‑3331 NIH‑452
GER (gastroesophageal reflux) + +
Telecanthus + +
Eczema + −
Hip dysplasia − +
Micropenis − +
Pectus excavatum − +
Growth retardation − +
Elbow dislocation, chronic − +
Comparison of the standard Joubert syndrome features with those reported for UDP-3331 and NIH-452. Additional features noted in the patients are listed
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Fig. 2 Cellular morphology and analysis of JBTS10 skin fibroblasts. a Co‑localization analysis of OFD1 (magenta) signals in proband, proband 
rescued, and adult WT cells with ɣ‑tubulin (red) and PCM1 (green). Inset higher magnification of the region outlined with dotted lines. b Immunofluo‑
rescence staining for OFD1 (green) and α‑tubulin (red) in fibroblasts of the proband (UDP‑3331), proband rescued (UDP‑3331 + OFD1), and adult 
WT control. c Comparison of endoplasmic reticulum structure (KDEL, green) in UDP‑3331 and WT cells. d Comparison of the cis‑ (GM‑130, green) and 
trans‑ (TGN‑46, red) Golgi in UDP‑3331 and WT cells. DNA was stained with Hoechst 33,342 (blue). All scale bars represent 20 µm
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JBTS10 patient cells and the ciliogenesis phenotype pre-
viously associated with OFD1 mutations.
The observed decrease in primary cilia stability fol-
lowing neuraminidase removal of sialic acids from the 
glycoproteome and the co-localization of sialylated gly-
coproteins with the primary cilium suggest that protein 
sialylation plays a role in ciliary homeostasis. We hypoth-
esize, therefore, that the abnormal glycosylation might 
contribute to the ciliogensis defect. Two factors, however, 
remain to be addressed. First, our glycomic studies on 
primary dermal fibroblasts were performed under growth 
conditions that do not promote ciliogenesis, and there-
fore, it is unclear how much of the abnormal glycosyla-
tion is attributable to ciliary proteins. Second, because of 
technical limitations to performing glycome profiling on 
the cilia, we are unable to assess biochemically whether 
the ciliary proteome is aberrantly glycosylated in patient 
cells. These two limitations provide testable hypotheses 
for future investigations.
Regardless of the impact directly on the ciliary pro-
teins, the accumulation of the sialic acid epitope that 
binds to the lectin SNA in the nuclei of JBTS10 patient 
cells and the increased CMP-SA and the accumulation 
of incompletely sialylated N-glycans are consistent with 
a defect in CMP-SA metabolism or transport. Unlike 
other nucleotide sugars, CMP-SA is synthesized in the 
nucleus, rather than the cytosol; thus, CMP-SA must 
be transported through two distinct membrane-bound 
organelles for proper sialylation to occur [32, 33]. There 
are many possible ways in which alterations in levels of 
functional OFD1 could lead to changes in sialylated gly-
coproteins. First, nuclear OFD1 [13] might contribute 
to CMP-SA metabolism. Second, defects of ciliogenesis 
might alter cell signaling [34–36] or the role of the basal 
body in regulating microtubules and intracellular trans-
port to impair CMP-SA transport from the nucleus and 
subsequent utilization in the Golgi. Disruption of the 
centrosome structure and tethering of the daughter cen-
trioles are associated with abnormal Golgi structure [37], 
and alterations in the structure of the Golgi cisternae 
would undoubtedly influence the glycosylation enzymes 
that are targeted specifically to cis- or trans-Golgi com-
partments [38]. However, we did not observe any obvious 
changes in centriole separation or Golgi structure. Third, 
the increased sialylation of O-linked core 1 T antigen on 
cellular proteins and the decreased sialylation of O-linked 
core 1 T antigen on secreted glycoproteins in plasma 
might suggest altered exocytosis and endocytosis of gly-
coproteins. Finally, elevated processing of sialoglycopro-
teins or enhanced turnover of surface sialoglycoproteins 
might contribute to the abnormal glycosylation signa-
ture observed [39]. Each of these potential mechanisms 
highlights the important role of ciliary and basal body 
proteins in cell physiology and the delicate homeostatic 
balance that can be indirectly disrupted by single-gene 
mutations.
Prior associations between primary ciliopathies and 
altered glycosylation have been limited to observations of 
the mutated ciliary proteins. Polycystin-2, polycystin-1, 
and aquaporin-11 mutations associate with abnormal 
glycosylation of ciliary proteins [40–42]. Changes in pro-
tein trafficking, which result in altered protein glycosyla-
tion, have been linked to polycystic liver disease [43].
There exists corroborating evidence that altered gly-
cosylation might contribute to the pathogenesis of some 
ciliopathies. Primary defects in glycosylation, collectively 
referred to as Congenital Disorders of Glycosylation 
(CDGs), cause phenotypes similar to those of primary cili-
opathies and disrupt cilia function. Defects in the N-linked 
Fig. 3 Analysis of ciliogenesis in JBTS10 and control skin fibro‑
blasts. a The percentage of ciliated cells following 48 h of serum 
starvation in UDP‑3331, UDP‑3331 + OFD1 rescue, adult WT, adult 
WT + OFD1 overexpression, UW172‑4, and fetal WT control cells. Error 
bars represent the 95% confidence interval for the average of three 
independent experiments. Asterisks indicate p < 0.001, Student’s t 
test. b Representative images of ciliated cells for the indicated cell 
lines. Acetylated tubulin (red) and ɣ‑tubulin (green) mark the cilia and 
basal body, respectively. DNA was stained with DAPI (blue). Scale bars 
10 µm
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glycosylation genes ALG3, ALG8, and ALG9, as well as the 
O-linked glycosylation gene B3GALTL, variably result in 
polycystic kidneys, cleft lip or palate, polycystic ovaries, 
and abnormal development of the brain including the cor-
pus callosum [44–47]. Mutations in GALNT11, encoding 
polypeptide N-acetylgalactosaminyltransferase, cause cili-
ary dysfunction and heterotaxy [48].
The importance of glycosylation in neural development 
is well illustrated by animal models of disrupted glyco-
sylation. A knock-out of the only sialyltransferase gene 
in D. melanogaster caused significant neurological symp-
toms, implicating sialylation as a key factor in neurode-
velopment and function [49]. Additionally, disruption 
of proteoglycan formation in C. elegans by alteration of 
microRNA levels causes aberrant migration of neurons 
[50]. Alterations of polysialic acid epitope formation in 
mice also cause abnormal neuronal development and 
disrupted neuron migration, likely due to changes in sia-
lylation of NCAM [51]. The cerebellum and midbrain 
anomalies that result in the molar tooth sign (MTS) are 
thought to arise due to aberrant migration of neurons in 
the cerebellum. Given that both N- and O-linked CDGs 
present with abnormal development of other brain struc-
tures, and animal models with altered sialylation show 
distinct neurodevelopment defects, it is possible that the 
altered glycosylation we observe in JBTS10 patients may 
contribute to the formation of MTS. Recent work by Feng 
and colleagues to identify the N-glycoproteome in the 
mouse brain revealed that several key proteins for brain 
development are N-glycosylated [52].
Table 2 Summary of N-glycan profiles of JBTS10 patient plasma
The percentages of total glycans for the indicated N-glycan species in the plasma of UDP-3331 and NIH-452 are shown along with reference (Ref ) range derived from 
controls. Species with values in the low-normal range in the JBTS10 samples are flagged with a pound sign (#). Species below the normal range in JBTS10 sample(s) 
are flagged with a dagger (†). Species that are elevated above the normal range are flagged with a caret (^)
# Low normal in JBST10
^ Above normal in JBST10









Ref low  
(% total glycans)
Ref high  
(% total glycans)
1580.2 Hex5 HexNAc2 0.69 0.91 0.23 1.88
1662.3 Hex3 HexNAc4 0.03 0.00 0.00 0.22
1784.4 Hex6 HexNAc2 0.51 0.48 0.00 0.87
1866.5 Hex4 HexNAc4 0.19 0.00 0.06 0.53
1982.5 Hex4 NeuAc1 HexNAc3 0.48 0.43 0.08 0.80
1988.5 Hex7 HexNAc2 0.19 0.00 0.00 0.39
2070.6 Hex5 HexNAc4 – 0.15 0.00 0.30
2156.7# Hex4 dHex1 HexNAc3 
NeuAc1
0.05 0.00 0.06 0.17
2186.7 Hex4 dHex1 NeuGc1 
HexNAc3
– 0.39 0.00 0.89
2192.7 Hex8 HexNAc2 0.32 0.00 0.06 0.61
2227.7^ Hex4 HexNAc4 NeuAc1 1.38 1.54 0.40 1.28
2285.2^ Hex4 dHex1 HexNAc5 0.17 – 0.00 0.16
2431.9^ Hex5 HexNAc4 NeuAc1 5.87 9.88 2.38 6.74
2606.0 Hex5 dHex1 HexNAc4 
NeuAc1
0.54 1.87 0.79 2.87
2793.3† Hex5 HexNAc4 NeuAc2 20.29 40.58 28.38 58.23
2966.5 Hex5 dHex1 HexNAc4 
NeuAc2
1.49 2.89 2.49 3.36
3241.6 Hex6 HexNAc5 NeuAc2 1.13 1.52 0.08 1.70
3415.6 Hex6 dHex1 HexNAc5 
NeuAc2
0.25 0.00 0.00 0.87
3602.9 Hex6 HexNAc5 NeuAc3 3.31 6.72 1.64 6.10
3776.6# Hex6 dHex1 HexNAc5 
NeuAc3
0.94 0.38 0.00 7.27
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Table 3 Summary of N-glycan profiles of JBTS10 patient fibroblasts
The percentages of total glycans of the indicated N-glycan species for UDP-3331, UDP-3331 + OFD1 rescue, UW172-4, and adult WT control fibroblasts samples are 
shown along with reference (Ref ) low and high values derived from control samples. Species with values in the low-normal range in the JBTS10 sample(s) are flagged 
with a pound sign (#). Species that are elevated above the normal range in JBTS10 sample(s) are flagged with a caret (^). Species below the normal range in JBTS10 
sample(s) are flagged with a dagger (†)
# Low normal in JBST10
^ Above normal in JBST10
† Below normal in JBST10
Centroid 
mass (m/z)
Glycan structure UDP‑3331 (% 
total glycans)
UDP‑3331 




Adult control (% 
total glycans)
Ref low (% total 
glycans)
Ref high (% total 
glycans)
1171.9 Hex3 HexNAc2 4.09 7.07 1.63 5.00 0.23 12.38
1346.0 Hex3 dHex1 
HexNAc2
3.86 5.28 1.06 5.09 0.00 6.11
1417.1# Hex3 HexNAc3 0.00 0.79 0.00 0.78 0.00 0.78
1580.2 Hex5 HexNAc2 8.19 11.68 4.55 8.46 1.83 14.29
1621.3 Hex4 HexNAc3 0.56 0.76 0.00 0.98 0.00 0.98
1662.3 Hex3 HexNAc4 0.00 0.00 0.00 0.00 0.00 0.29
1784.4 Hex6 HexNAc2 19.88 17.97 15.17 18.31 6.54 20.74
1825.4 Hex5 HexNAc3 0.57 0.62 0.00 0.90 0.00 0.90
1866.5 Hex4 HexNAc4 0.74 0.81 0.00 0.66 0.00 0.70
1982.5 Hex4 NeuAc1 
HexNAc3
0.00 0.00 0.00 0.00 0.00 0.30
1988.5 Hex7 HexNAc2 9.81 9.62 12.04 9.67 4.87 14.86
2029.6 Hex6 HexNAc3 0.54 0.52 0.00 0.93 0.00 2.19
2070.6 Hex5 HexNAc4 4.39 4.03 2.03 3.20 0.00 3.88
2156.7# Hex4 dHex1 
HexNAc3 
NeuAc1
0.00 0.34 0.00 0.52 0.00 0.75
2192.7 Hex8 HexNAc2 16.18 13.96 27.66 16.04 0.00 32.90
2227.7 Hex4 HexNAc4 
NeuAc1
0.00 0.00 0.00 0.00 0.00 0.20
2396.9 Hex9 HexNAc2 9.28 7.49 18.11 9.09 0.24 32.34
2431.9^ Hex5 HexNAc4 
NeuAc1
2.18 1.47 2.92 1.83 0.00 1.83
2606.0^ Hex5 dHex1 
HexNAc4 
NeuAc1
6.85 4.19 2.23 4.70 0.00 4.70
2793.3 Hex5 HexNAc4 
NeuAc2
0.86 0.45 1.53 1.00 1.21 6.80
2967.3 Hex5 dHex1 
HexNAc4 
NeuAc2
2.69 1.45 4.74 2.02 3.38 10.79
3241.6 Hex6 HexNAc5 
NeuAc2
0.00 0.00 0.00 0.17 0.00 1.96
3415.6 Hex6 dHex1 
HexNAc5 
NeuAc2
0.45 0.22 0.84 0.39 0.43 5.84
3602.9† Hex6 HexNAc5 
NeuAc3
0.33 0.00 0.00 0.28 0.64 23.23
3776.6# Hex6 dHex1 
HexNAc5 
NeuAc3
0.21 0.00 0.79 0.11 0.00 5.46
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Fig. 4 Lectin staining for sialic acid epitopes in JBTS10 and control skin fibroblasts. a Lectin staining of α‑2,6‑sialic acid (SNA, green) and α‑2,3‑sialic 
acid (MALII, blue) linkages in affected, rescued and control cells, as indicated. Arrows indicate atypical nuclear staining by SNA in UDP‑3331. Scale 
bars 20 µm. b Quantification of the fluorescence signal for SNA in nucleus relative to the entire cell for affected, rescued, and control cells under 
paraformaldehyde fixation conditions. Error bars represent standard error. Single asterisks indicate p < 0.05; double asterisks indicate p < 0.001 relative 
to both adult and pediatric male controls (unpaired, heteroscedastic t test). c Comparison of methanol and paraformaldehyde fixation on the rela‑
tive SNA staining intensity of the nucleus vs. the whole cell. Double asterisks indicate p < 0.001(unpaired, heteroscedastic t test). Error bars represent 
standard error
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Fig. 5 Nucleotide sugar analysis in JBTS10 and control skin fibroblasts. a Representative HPAEC trace for UDP‑3331, UDP‑3331 + OFD1 rescue, adult 
WT, adult WT + OFD1 overexpression, pediatric male control cells, and 500 nM standard CMP‑sialic acid. b Quantification of CMP‑sialic acid levels in 
affected and control cells (in μM) (single asterisks indicate p < 0.005 in an unpaired, heteroscedastic t test). Error bars represent standard error
(See figure on next page.) 
Fig. 6 Neuraminidase treatment of adult WT primary cells. a Average cilia length of WT cells with and without neuraminidase (±Neuase) treat‑
ment to remove sialic acids from glycan chains; neuraminidase treatment significantly reduced average cilia length by ~1 µm. Error bars represent 
standard error; p < 0.001 as determined in an unpaired, heteroscedastic t test. b The percentage of ciliated cells is decreased after neuraminidase 
treatment; p < 0.05 as determined by a two‑tailed Fisher’s Exact t test; error bars represent the 95% confidence interval for the binomial distribu‑
tion represent by the sample population. c, d Representative images of WT fibroblasts without (c) and with (d) neuraminidase treatment. Cilia are 
stained with ARL13B antibody (red) and ɣ‑tubulin (green). Scale bars 20 µm. e Lectin staining for sialic acid with SNA (green) and MAL II (white) and 
galactose with PNA (red) in WT fibroblasts with DRAQ5 DNA counterstaining (blue). f Representative image of SNA (green) signal showing alpha 
2,6‑sialylation co‑localizing with ARL13B‑positive cilia (red) in WT cells without neuraminidase treatment. Scale bars 5 µm
Page 15 of 18Kane et al. Cilia  (2017) 6:2 
Page 16 of 18Kane et al. Cilia  (2017) 6:2 
Conclusions
Our findings highlight a potential role for glycosylation 
in contributing to pathogenesis of JBST10 and possibly 
other ciliary disorders. The mechanism for the altered 
glycosylation remains to be determined. Our observa-
tions raise the question as to whether glycosylation is 
altered in other types of Joubert syndrome and more 
severe ciliopathies. The impact of altered glycosylation in 
contributing to pathophysiology in ciliopathies bears fur-
ther study.
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